Published in final edited form as:

Carbohydr Res. 2015 April 30; 407: 148–153. doi:10.1016/j.carres.2015.02.005.

C-glycosphingolipid precursors via iodocyclization of homoallylic trichloroacetimidates

Ahmad S. Altit[†] and David R. Mootoo^{*}

Department of Chemistry, Hunter College, 695 Park Avenue New York, NY 10065 and The Graduate Center, CUNY, 365 5th Avenue, New York, NY 10016

Abstract

The iodocyclization of homoallylic trichloroacetimidates derived from α -C-allyl galactoside were investigated. In line with the stereochemical trend observed for less substituted non-glycosylated frameworks, *E* and *Z* substrates delivered stereoselectively the 1,3-*anti* and 1,3-*syn* amino alcohol motifs, respectively. These products are advanced precursors to C-glycosides of the potent immunostimulatory glycolipid KRN7000.

Graphical abstract

Keywords

glycomimetic; C-glycoside; glycolipid; KRN7000; imidate; oxazine; iodocyclization

^{*}Corresponding author. dmootoo@hunter.cuny.edu; Fax.: 212 772 5332; Tel.: 212 772 4356.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain

Supplementary data

Supplementary data associated with this article can be found, in the online version, at

1. Introduction

The involvement of glycosphingolipids in a variety of biological pathways has created a demand for unnatural analogues for use as mechanistic probes.^{1,2,3,4,5,6,7,8} A popular subset thereof are C-glycosides, which are of interest because of their greater hydrolytic stability and conformational mobility compared to their parent O-glycosides.^{9,10,11,12,13} However, the synthesis of these materials are not trivial, with a major challenge being the stereoselective fabrication of the pseudoanomeric bond, which is exacerbated for structures with highly substituted aglycone segments, as in the case of C-glycosphingolipids. One solution to this problem is to elaborate simple C-glycosides in which the pseudoanomeric configuration is “pre-set”.^{14,15,16,17,18,19,20,21,22,23,24} In this vein C-allyl glycosides of a variety of different monosaccharides are available in either pseudoanomeric configuration,^{25,26,27,28,29} and new approaches for their transformation to more functionalized C-glycosides are of interest.

Towards this end, we have recently reported a strategy in which C-allylglycosides **1** are converted to homoallylic alcohol derivatives **2**, which serve as templates to C-glycosphingolipids **5** via an intramolecular nitrogen delivery strategy (Scheme 1). Our initial execution of this plan utilized the iodocyclization of a homoallylic carboimidothioate **3**.³⁰ Herein, we describe our results on the cyclization of related trichloroacetimidates **4**. These studies were directed at C-glycosides of the potent immunostimulatory glycolipid KRN7000 **9** (Scheme 2).³¹

2. Results and Discussion

Synthetic design

The specific templates **6** and **7**, chosen for this study were of interest because of their easily availability from known precursors, and their potential as versatile relay compounds to C-glycosides of KRN7000 and related sphingolipids (Scheme 2). Studies on the iodocyclization of simple homoallylic trichloroacetimidates suggest that the stereochemistry of this cyclization depends primarily on alkene geometry and the configuration at the allylic position.^{32,33,34} Thus, the reaction of *E*-alkene **6** is expected to favor the 1,3-*anti* amino alcohol motif (cf **22** *vide infra*), which would lead to the “unnatural” stereochemistry in C-KRN7000 (i.e. **8a**), because of stereoelectronic factors due to the allylic oxygen. In contrast, the reaction of the *Z*-isomer **7** is predicted to give the 1,3-*syn* amino alcohol derivative (cf **23**, *vide infra*), because A^(1,3) strain overrides the directing effect of the allylic substituent. However, because of the highly substituted nature of **6** and **7**, and the conformational rigidity imposed by the cyclic acetal framework, neither the expected stereoselectivity nor chemoselectivity in these reactions was assured. With regards to the latter, to reduce the likelihood of deleterious THF formation involving the C2-oxygen on the sugar ring, the 2-OH on the sugar segment was protected as an acetate.^{15,23,35}

Synthesis

We envisaged that a cross metathesis (CM) strategy would provide the desired *E* and *Z* frameworks in a single step, with the former as the major isomer.^{17,30,36} Accordingly, CM

on known alkenes, C-allyl galactoside **11**³⁵ and the glucose derived alkene **12**³⁷ (6 equivalents), using Grubbs II catalyst, produced an *E:Z* mixture of homoallylic alcohols **13** and **14** in 90% yield from **12**, as an approximately 3:1 *E:Z* mixture, as determined by ¹H NMR analysis. *J*_{vic} values of 15.7 and 11.0 Hz for **13** and **14** respectively, supported the assigned alkene geometry. Treatment of **13** and **14** with DBU and trichloroacetonitrile provided the respective trichloroacetimidates **6** and **7**.

A more stereoselective synthesis of the *Z*-homoallylic alcohol **14** was performed using a Wittig olefination strategy. Thus, C-allyl glycoside **10** was converted to alcohol **16** through standard procedures for alcohol silylation and alkene processing. Transformation of **16** to the iodide **17** and reaction of the latter with triphenylphosphine provided phosphonium salt **18**. The use of the *tert*-butyldimethylsilyl protecting group was important for this synthesis as benzyl and *p*-methoxybenzyl ethers were found to give appreciable amounts of the tetrahydrofuran product resulting from nucleophilic attack by the C2-oxygen, during the iodination step.^{15,23} Aldehyde **20** was obtained from **12** after alcohol benzylation and ozonolysis of the alkene. Treatment of **18** in a mixture of THF and dichloromethane at -78 °C with NaHMDS, followed by addition of **20** to the resulting ylide, provided alkene **21** in 46% yield from **18**, as exclusively the *Z* isomer within the limits of ¹H NMR detection. The solvent mixture for this reaction was critical as pure THF gave lower *Z:E* ratios. This result may be due to a higher effective concentration of the metal cation in the reaction with pure THF, which facilitates oxaphosphetane reversion, and consequently stereochemical drift.^{38,39} That the relative configuration at the α-carbon in **20** was unaffected by epimerization under the conditions of the Wittig reaction, was confirmed by correlation of the Wittig product **21** with the *Z*-alkene **14** from the CM route, and by NMR analysis of **23**, the oxazine subsequently obtained from **14** (*vide infra*). Thus, exchange of the protecting group at the C2-OH of the sugar residue in **21** from the silyl ether to the acetate, followed by DDQ promoted removal of the *p*-methoxybenzyl ether afforded **14** in 93 % overall yield from **21**.

Treatment of a solution of the *E*-homoallylic trichloroacetimidate **6** in dry propionitrile with IBr, in the presence of anhydrous K₂CO₃ at -78 → -25 °C, gave oxazine **22** in approximately 62% yield. Under similar conditions the *Z*-trichloroacetimidate **7** gave oxazine **23** in 70% yield. In contrast to the iodocyclizations of related carboimidothioate substrates where iodonium dicollidine perchlorate (IDCP) was favored as the promoter over IBr, the more reactive IBr was preferred here because of the apparently lower reactivity of the trichloroacetimidate substrates. The structures of **22** and **23** were assigned from 2D COSY, HSQC and NOESY experiments. The stereochemistry of the newly formed oxazine ring in **22** was deduced from *J*_{2',3'} and *J*_{3',4'} values of 7.0 and 10.3 Hz respectively, and a *H*_{3'/5'} nOe. That the *J*_{2',3'} is 7.0 Hz and not much lower, suggests that six membered ring adopts a distorted half chair conformation. Similarly, *J*_{2',3'} and *J*_{3',4'} values of 8.8 and 10 Hz respectively, and *H*_{2'/4'} and *H*_{3'/5'} nOes supported the structure of **23**. In this case the relatively large *J*_{2',3'} of 8.8 Hz suggests a less distorted conformation of the oxazine ring.

3. Conclusion

Thus, the iodocyclizations of homoallylic trichloroacetimidates **6** and **7** showed opposite facial selectivity, resulting in the 1,3-*syn* and 1,3-*anti* aminoalcohol motifs respectively. This stereochemical trend is line with results reported for less substituted non-glycosylated substrates, but differs to our earlier result for related carboimidothioates, in which the *E* and *Z* substrates showed the same facial selectivity.^{30,32,33} However, since the trichloroacetimidates in the present study are conformationally restrained by the cyclic acetal framework, whereas the analogous carboimidothioates were not, it is unclear whether the contrasting stereochemical trends are a consequence of the different imide nucleophiles or the greater rigidity of the trichloroacetimidate substrates. It is also unclear whether highly substituted sugar ring impacts on the stereoselectivity of these iodocyclizations. More systematic are needed for a clearer understanding of the stereochemistry of these complex imide cyclizations. These and applications to the synthesis of C-glycosides of KRN7000 and related glycosphingolipids are underway.

4. Experimental

4.1 Synthesis – General

Solvents were purified by standard procedures or used from commercial sources as appropriate. Petroleum ether refers to the fraction of petroleum ether boiling between 40 and 60 °C. Ether refers to diethyl ether. Unless otherwise stated thin layer chromatography (TLC) was done on 0.25 mm thick precoated silica gel 60 (HF-254, Whatman) aluminium sheets and flash column chromatography (FCC) was performed using Kieselgel 60 (32–63 mesh, Scientific Adsorbents). Elution for FCC usually employed a stepwise solvent polarity gradient, correlated with TLC mobility. Chromatograms were observed under UV (short and long wavelength) light, and/or were visualized by heating plates that were dipped in a solution of ammonium (VI) molybdate tetrahydrate (12.5 g) and cerium (IV) sulfate tetrahydrate (5.0 g) in 10% aqueous sulphuric acid (500 mL), or a solution of 20% sulfuric acid in ethanol. NMR spectra were recorded using a Varian Unity Plus 500 instrument. ¹H and ¹³C spectra were recorded at 500 and 125 MHz respectively in CDCl₃ or C₆D₆ solutions with residual CHCl₃ or C₆H₆ as internal standard (δ_{H} 7.27, 7.16 and δ_{C} 77.2, 128.4 ppm). Optical rotations ($[\alpha]_{\text{D}}$) were recorded using a Jasco P-1020 polarimeter and are given in units of 10⁻¹ degcm²g at 589 nm (sodium D-line). Chemical shifts are quoted in ppm relative to tetramethylsilane (δ_{H} 0.00) and coupling constants (J) are given in Hertz. First order approximations are employed throughout. High resolution mass spectrometry was performed on Ultima Micromass Q-TOF or Waters Micromass LCT Premier mass spectrometers.

4.2 *E* Homoallylic trichloroacetimidate (**6**)

To a solution of **13** (150 mg, 0.215 mmol) in dry CH₃CH₂CN (3.0 mL) at –25 °C was added DBU (100 μ L, 0.70 mmol) and CCl₃CN (100 μ L, 0.99 mmol). The reaction mixture was stirred at this temperature for 20 min, then diluted with water and extracted with EtOAc. The organic phase was washed with brine and dried (Na₂SO₄), filtered, and concentrated in *vacuo*. The crude residue was purified by FCC to give **6** (185 mg, 92%): *R*_f = 0.35 (20%

EtOAc/hexane); ^1H NMR (CDCl_3) δ 8.39 (s, 1H), 7.43-7.17 (m, 20H), 5.75 (m, 1H), 5.56 (dd, J = 6.7, 15.6 Hz, 1H), 5.49 (s, 1H), 4.97 (m, 1H), 4.89 (m, 1H), 4.62-4.40 (m, 7H), 4.22 (dd, J = 6.8, 9.4 Hz, 1H), 4.09 (m, 1H), 3.94 (m, 1H), 3.85 (m, 1H), 3.82 (dd, J = 3.0, 5.0 Hz, 1H), 3.67-3.62 (m, 3H), 2.33-2.05 (m, 2H), 1.95 (s, 3H). ^{13}C NMR (CDCl_3) δ 170.3, 161.6, 138.7, 138.3, 138.2, 137.5, 131.1, 129.3, 128.8, 128.6, 128.5, 128.0, 127.9, 127.8, 126.5, 101.5, 79.8, 77.7, 76.8, 75.0, 74.0, 73.5, 73.4, 73.1, 72.5, 71.0, 70.6, 67.5, 66.6, 32.5, 21.2. HRMS (ESI, MNa^+) m/z calc for $\text{C}_{44}\text{H}_{46}\text{Cl}_3\text{NNaO}_9$ 860.2136, found 862.2098.

4.3 Z Homoallylic trichloroacetimidate (7)

To a solution of **14** (120 mg, 0.173 mmol) in dry $\text{CH}_3\text{CH}_2\text{CN}$ (2 mL) at -25°C was added DBU (100 μL , 0.70 mmol), and CCl_3CN (100 μL , 0.99 mmol). The reaction was processed as described for the synthesis of the *E*-trichloroacetimidate **6**, and the crude material purified by FCC to give **7** (100 mg, 70%): R_f = 0.50 (20% EtOEt/hexane); ^1H NMR (CDCl_3) δ 8.39 (s, 1H), 7.43-7.17 (m, 20H), 5.66 (m, 1H), 5.52 (m, 2H), 4.93 (m, 1H), 4.89 (dt, J = 5.2, 9.8 Hz, 1H), 4.61-4.43 (m, 8H), 4.15 (m, 1H), 3.93 (m, 2H), 3.78 (dd, J = 3.0, 5.4 Hz, 1H), 3.65 (m, 3H), 2.40-2.27 (m, 2H), 1.93 (s, 3H). ^{13}C NMR (CDCl_3) δ 170.3, 161.8, 138.7, 138.3, 138.2, 137.4, 131.8, 129.4, 128.6, 128.5, 128.0, 127.9, 127.4, 126.5, 101.5, 77.5, 75.6, 74.7, 74.5, 73.4, 73.2, 71.2, 71.0, 67.6, 66.4, 28.9, 21.2. HRMS (ESI, MNa^+) m/z calc for $\text{C}_{44}\text{H}_{46}\text{Cl}_3\text{NNaO}_9$ 860.2136, found 862.2118.

4.4 1-(2'-O-acetyl-3',4',6'-tri-O-benzyl- α -D-galactopyranosyl)-2-propene (11)

To a solution of **10** (250 mg, 0.53 mmol) in EtOAc (9 mL) at rt, was added DMAP (6.5 mg, 0.053 mmol) and Ac_2O (100 μL , 0.97 mmol). The reaction mixture was stirred for 20 min, then concentrated *in vacuo*, and the residue purified by FCC to give **11** (250 mg, 92%): R_f = 0.45 (20% EtOEt/hexane); ^1H NMR (CDCl_3) δ 7.22-7.19 (m, 15H), 5.65 (m, 1H), 5.00-4.95 (m, 3H), 4.64-4.45 (m, 6H), 4.16 (m, 1H), 3.95 (m, 2H), 3.83 (dd, J = 3.0, 5.2 Hz, 1H), 3.68 (m, 2H), 2.27-2.09 (m, 2H), 1.97 (s, 3H). ^{13}C NMR (CDCl_3) δ 170.2, 138.5, 138.2, 138.1, 134.0, 128.4, 127.8, 127.7, 127.6, 127.5, 117.3, 74.7, 74.0, 73.3, 73.1, 73.0, 72.1, 70.8, 68.7, 66.2, 33.9, 21.0.

4.5 CM of 11 and 12: E- and Z-homoallylic alcohols (13) and (14)

Ethylene gas was bubbled through a mixture of **11** (250 mg, 0.49 mmol) and **12** (600 mg, 2.9 mmol) in dry dichloromethane (50 mL) for 1 h. Grubbs II catalyst (42 mg, 0.04 mmol) was then added and the reaction mixture heated at reflux for 2 h. The solvent was concentrated *in vacuo* and the crude mixture was subjected to FCC to give a mixture of *E* alkene **13**, *Z* alkene **14** (305 mg, 90% based on **11**; *E*:*Z* ca 3:1). Repeat FCC afforded partial separation of *E* and *Z* alkenes, **13** and **14**.

For **13**: R_f = 0.22 (40% EtOAc/hexane); ^1H NMR (CDCl_3) δ 7.25-7.15 (m, 20H), 5.62 (m, 1H), 5.43 (m, 1H), 5.39 (dd, J = 8.4, 15.7 Hz, 1H), 4.89 (m, 1H), 4.61-4.41 (m, 6H), 4.23 (m, 2H), 4.04 (t, J = 10.6 Hz, 1H), 3.90 (m, 1H), 3.85 (t, J = 8.6 Hz, 1H), 3.79 (dd, J = 3.0, 5.8 Hz, 1H), 3.64-3.52 (m, 3H), 3.43 (m, 1H), 3.03 (d, J = 4.4 Hz, 1H), 2.34 (m, 1H), 2.13 (m, 1H), 2.02 (s, 3H). ^{13}C NMR (CDCl_3) δ 171.3, 138.5, 138.1, 138.0, 137.9, 131.6, 130.1, 128.9, 128.4, 128.3, 127.9, 127.8, 127.7, 127.6, 126.2, 101.0, 83.9, 76.8, 74.5, 73.1, 73.0,

70.7, 70.4, 64.8, 33.4, 21.1. HRMS (ESI, MNa^+) m/z calc for $C_{42}H_{46}NaO_9$ 717.3040, found 717.3039.

For **14**: R_f = 0.26 (40% EtOAc/hexane); 1H NMR ($CDCl_3$) δ 7.38-7.20 (m, 20H), 5.57 (dt, J = 11.0, 4.7 Hz, 1H), 5.47 (m, 2H), 5.00 (m, 1H), 4.66-4.40 (m, 7H), 4.25 (m, 2H), 4.17 (m, 1H), 4.02 (d, J = 10.5 Hz, 1H), 3.95 (t, J = 11 Hz, 1H), 3.84 (dd, J = 17.9, 5.25 Hz, 1H), 3.70 (dd, J = 5.1, 3.0 Hz, 1H), 3.56 (m, 3H), 3.38 (dt, J = 9.5, 5.4 Hz, 1H), 2.50 (m, 1H), 1.98 (m, 4H). ^{13}C NMR ($CDCl_3$) δ 170.5, 138.3, 138.2, 138.9, 137.9, 131.4, 129.7, 129.2, 128.6, 128.5, 128.1, 128.0, 127.9, 126.4, 101.0, 78.6, 74.3, 73.6, 73.3, 72.4, 72.0, 71.0, 65.1, 29.2, 21.2. HRMS (ESI, MNa^+) m/z calc for $C_{42}H_{46}NaO_9$ 717.3040, found 717.3037.

4.6 1-(2'-O-tert-butyldimethylsilyl-3',4',6'-tri-O-benzyl- α -D-galactopyranosyl)-2-propene (15)

TBSCl (1.4 g, 9.2 mmol) and NaH (212 mg, 8.9 mmol) were added to a solution of alcohol **10** (1.4 g, 2.95 mmol) in dry THF (10 mL). The reaction mixture was stirred at rt for 1 h. The reaction was diluted with water and extracted with EtOAc. The organic phase was washed with brine, dried (Na_2SO_4), filtered, and concentrated *in vacuo*. The residue was purified by FCC to give **15** (1.74 g, 98%): R_f = 0.47 (10% EtOAc/hexane); 1H NMR ($CDCl_3$) δ 7.32-7.30 (m, 15H), 5.78 (m, 1H), 5.00 (m, 2H), 4.68-4.41 (m, 6H), 3.97 (m, 1H), 3.90 (m, 2H), 3.86 (ddd, J = 9.8, 9.0, 4.1 Hz, 1H), 3.77 (t, J = 10.5 Hz, 1H), 3.62 (dd, J = 10.6, 4.7 Hz, 1H), 3.50 (dd, J = 7.0, 2.7 Hz, 1H), 2.27 (m, 2H), 0.83 (s, 9H), 0.00 (s, 3H), -0.06 (s, 3H). ^{13}C NMR ($CDCl_3$) δ 138.8, 138.7, 135.7, 128.5, 128.5, 128.1, 127.9, 127.8, 127.7, 127.6, 116.7, 78.5, 74.2, 73.4, 73.2, 73.2, 72.7, 70.3, 67.7, 32.0, 26.0, 18.2, -4.5, -4.7. HRMS (ESI, MH^+) m/z calc for $C_{36}H_{49}O_5Si$ 589.3349, found 589.3346.

4.7 1-(2'-O-tert-butyldimethylsilyl-3',4',6'-tri-O-benzyl- α -D-galactopyranosyl)-2-ethanol (16)

A stream of O_3/O_2 was passed through a solution of **15** (1.0 g, 1.7 mmol) in CH_2Cl_2 (150 mL) at -78 °C for 10 min. The reaction mixture was then purged with nitrogen, PPh_3 (500 mg, 1.9 mmol) added and stirring continued at rt for 2 h. At this point the mixture was concentrated *in vacuo*. FCC of the residue afforded the derived aldehyde (0.85 g, 85%): R_f = 0.50 (20% EtOAc/hexane); 1H NMR ($CDCl_3$) δ 9.75 (s, 1H), 7.32-7.30 (m, 15H), 4.73-4.5 (m, 7H), 4.03 (m, 1H), 4.00 (m, 1H), 3.96 (m, 1H), 3.86 (t, J = 10.3 Hz, 1H), 3.68 (dd, J = 10.6, 4.5 Hz, 1H), 3.54 (dd, J = 6.7, 2.5 Hz, 1H), 2.62 (m, 2H), 0.83 (s, 9H), 0.00 (s, 3H), -0.05 (s, 3H). ^{13}C NMR ($CDCl_3$) δ 201.3, 138.5, 128.6, 128.5, 128.0, 127.9, 127.8, 127.7, 78.2, 73.7, 73.4, 73.3, 70.1, 68.2, 67.3, 42.9, 26.0, 18.2, -4.5, -4.7. HRMS (ESI, MH^+) m/z calc for $C_{35}H_{46}O_6Si$ 591.3142, found 591.3146.

$NaBH_4$ (125 mg, 3.5 mmol) was slowly added to a solution of the material from the previous step in methanol (20 mL) at 0 °C. The reaction mixture was stirred for 30 min, then diluted with saturated aqueous NH_4Cl and evaporated under reduced pressure. The residual syrup was taken up in EtOAc and washed with saturated aqueous $NaHCO_3$ and brine. The organic extract was dried (Na_2SO_4), filtered and concentrated *in vacuo*. FCC of the residue provided **16** as a colorless oil (730 mg, 86%): R_f = 0.25 (20% EtOAc/hexane); 1H NMR ($CDCl_3$) δ 7.32-7.30 (m, 15H), 4.71-4.50 (m, 6H), 4.09 (m, 2H), 3.98 (t, J = 10.05 Hz, 1H), 3.89 (m, 2H), 3.75 (m, 2H), 3.55 (dd, J = 6.6, 2.8 Hz, 1H), 3.51 (dd, J = 10.7, 3.5 Hz, 1H), 1.90 (m,

1H), 1.61 (m, 1H), 0.83 (s, 9H), 0.00 (s, 3H), -0.05 (s, 3H). ^{13}C NMR (CDCl_3) δ 138.7, 138.5, 138.3, 128.7, 128.6, 128.5, 128.2, 128.1, 128.0, 127.9, 127.8, 127.7, 78.4, 74.0, 73.4, 73.0, 72.4, 70.8, 67.8, 61.7, 30.0, 26.2, 26.0, 25.9, 25.8, 18.2, -4.6, -4.7. HRMS (ESI, MNa^+) m/z calc for $\text{C}_{35}\text{H}_{48}\text{NaO}_6\text{Si}$ 615.3118, found 615.3112.

4.8 1-(2'-O-tert-butyldimethylsilyl-3',4',6'-tri-O-benzyl- α -D-galactopyranosyl)-2-iodoethane (17)

I_2 (673 mg, 2.65) was added to a mixture of alcohol **16** (630 mg, 1.06 mmol), Ph_3P (837 mg, 3.48 mmol) and imidazole (289 mg, 4.24 mmol) in toluene (20 mL). The reaction mixture was stirred at rt for 30 min, then quenched with 10% aqueous $\text{Na}_2\text{S}_2\text{O}_3$ and extracted with EtOAc. The organic phase was washed with brine, dried (Na_2SO_4) and concentrated *in vacuo*. FCC of the residue gave **17** as a colorless oil (691 mg, 93%): R_f = 0.6 (10% EtOAc/hexane); ^1H NMR (CDCl_3) δ 7.30-7.23 (m, 15H), 4.70-4.45 (m, 6H), 3.99 (ddd, J = 10.6, 6.9, 3.5 Hz, 1H), 3.93-3.89 (m, 2H), 3.67 (dd, J = 10.4, 4.1 Hz, 1H), 3.49 (dd, J = 6.9, 2.6 Hz, 1H), 3.27 (m, 1H), 3.18 (m, 1H), 2.05 (m, 1H), 1.92 (m, 1H), 0.82 (s, 9H), 0.00 (s, 3H), -0.06 (s, 3H). ^{13}C NMR (CDCl_3) δ 138.7, 138.6, 128.7, 128.6, 128.5, 128.4, 128.1, 128.0, 127.9, 127.8, 127.7, 78.8, 74.1, 73.6, 73.2, 72.9, 70.4, 68.1, 31.8, 26.2, 26.0, 25.9, 25.8, 18.2, 3.6, -4.6, -4.7. HRMS (ESI, MNa^+) m/z calc for $\text{C}_{35}\text{H}_{47}\text{INaO}_5\text{Si}$ 725.2135, found 725.2131.

4.9 1-(2'-O-tert-butyldimethylsilyl-3',4',6'-tri-O-benzyl- α -D-galactopyranosyl)-2-triphenylphosphoniummethyl iodide (18)

A mixture of **17** (691 mg, 0.984 mmol) and PPh_3 (2.24 g, 8.5 mmol) was fused at 80 °C for 3 h. The mixture was then cooled to rt and purified by FCC to give **18** (845 mg, 88%): R_f = 0.16 (10% acetone/ CH_2Cl_2); ^1H NMR (CDCl_3) δ 7.75 (m, 15 H), 7.65 (m, 15H), 4.61-4.47 (m, 6H), 4.13 (m, 2H), 4.04 (m, 1H), 3.86 (m, 1H), 3.75 (m, 1H), 3.69 (1H), 3.65 (d, J = 7.6 Hz, 1H), 3.62 (dd, J = 5.7, 2.8 Hz, 1H), 3.43 (m, 1H), 2.07-1.83 (m, 2H), 0.60 (s, 9H), -0.20 (s, 3H), -0.28 (s, 3H). ^{13}C NMR (CDCl_3) δ 139.0, 138.5, 135.2, 134.0, 133.9, 130.8, 130.7, 128.6, 128.5, 128.1, 128.0, 127.9, 127.7, 127.6, 118.4 ($J_{\text{C-P}}$ = 85.8 Hz), 73.9, 73.6, 73.5, 73.0, 72.4, 70.3, 68.1, 25.9, 23.2, 19.5 ($J_{\text{C-P}}$ = 52.4 Hz), 18.0, -4.6, -4.9. HRMS (ESI, M-I) m/z calc for $\text{C}_{53}\text{H}_{62}\text{O}_5\text{PSi}$ 837.4104, found 837.4102.

4.10 (2R,4S,5R)-5-((4-methoxybenzyl)oxy)-2-phenyl-4-vinyl-1,3-dioxane (19)

To a solution of **12** (1.0 g, 4.9 mmol) in dry DMF (20 mL) at 0 °C was added NaH (213 mg, 5.3 mmol). The mixture was stirred at this temperature for 15 min, at which time PMBCl (1.0 mL, 7.2 mmol) was added slowly, and stirring continued at rt for 2 h. The mixture was then quenched with methanol (0.5 mL), diluted with water and extracted with EtOAc. The organic phase was washed with brine, dried (Na_2SO_4), filtered, and concentrated *in vacuo*. FCC of the residue provided **19** (1.4 g, 86%): R_f = 0.55 (20% EtOAc/hexane); ^1H NMR (CDCl_3) δ 7.48 (d, J = 1.8 Hz, 2H), 7.32 (m, 3H), 7.23 (d, J = 9.2 Hz, 2H), 6.86 (d, J = 8.6 Hz, 2H), 6.03 (ddd, J = 17.3, 10.8, 5.8 Hz, 1H), 5.35 (dd, J = 95.8, 16.8, Hz 2H), 4.45 (m, 2H), 4.25 (dd, J = 10.9, 5.1 Hz, 1H), 4.12 (dd, J = 9.2, 5.9 Hz, 1H), 3.79 (s, 3H), 3.62 (t, J = 10.4, 1H), 3.42 (dt, J = 9.5, 5.1 Hz, 1 H). ^{13}C NMR (CDCl_3) δ 159.7, 137.9, 135.2, 130.1,

129.8, 129.6, 129.1, 128.4, 126.4, 101.0, 81.5, 72.8, 72.7, 69.9, 55.5. HRMS (ESI, MNa⁺) *m/z* calc for C₂₀H₂₂NaO₅ 349.1416, found 349.1413.

4.11 (2*R*,4*R*,5*R*)-5-((4-methoxybenzyl)oxy)-2-phenyl-1,3-dioxane-4-carbaldehyde (**20**)

Alkene **19** (1.00 g, 3.06 mmol) was subjected to the standard ozonolysis procedure described in the preparation of **16**. FCC of the crude reaction product afforded **20** (500 mg, 50%): *R_f* = 0.17 (20% EtOAc/hexane); ¹HNMR (CDCl₃) 9.72 (d, *J* = 1.0 Hz, 1H), 7.46 (m, 2H), 7.35 (m, 3H), 7.25 (m, 2H), 6.88 (d, *J* = 8.7 Hz, 2H), 5.51 (s, 1H), 4.55 (ABq, δ = 0.04 ppm, *J* = 11.3 Hz, 2H), 4.29 (dd, *J* = 5.1, 10.8 Hz, 1H), 4.18 (d, *J* = 9.7 Hz, 1H), 3.78 (s, 3H), 3.74 (m, 1H), 3.65 (m, 1H). ¹³CNMR (CDCl₃) δ 197.3, 159.9, 137.0, 130.1, 129.5, 128.6, 126.4, 114.2, 101.1, 83.0, 72.7, 69.6, 67.9, 55.5. HRMS (ESI, MNa⁺) *m/z* calc for C₁₉H₂₀NaO₅ 351.1208, found 351.1209.

4.12 *Z*-*p*-Methoxybenzyl ether (**21**)

NaHMDS (0.57 mL of a 2M solution in THF, 1.14 mmol) was added at -78 °C to a solution of **18** (1.10 g, 1.14 mmol) in anhydrous 2:1 THF/CH₂Cl₂ (24 mL). The resulting bright orange solution was stirred for 1 h at this temperature, at which time a solution of **20** (450 mg, 1.37 mmol) in THF (10 mL) was added dropwise. The resulting mixture was warmed to rt over 5 h, then poured into saturated aqueous NH₄Cl and extracted with EtOAc. The organic phase was washed with brine, dried (Na₂SO₄), filtered, and evaporated under reduced pressure. FCC of the residue gave **21** (385 mg, 46%): *R_f* = 0.23 (10% EtOAc/hexane); ¹HNMR (CDCl₃) δ 7.38-7.20 (m, 22H), 6.8 (m, 2H), 5.8 (m, 1H), 5.6 (t, *J* = 9.6 Hz, 1H), 5.45 (s, 1H), 4.75-4.40 (m, 10H), 4.20 (m, 1H), 4.04 (m, 1H), 3.94 (m, 3H), 3.89 (m, 1H), 3.32 (m, 1H), 3.79 (s, 3H), 3.64 (m, 1H), 3.57 (m, 1H), 3.47 (m, 1H), 3.42 (m, 1H), 2.6-2.4 (m, 2H), 0.86 (s, 9H), -0.02 (s, 3H), -0.08 (s, 3H). ¹³CNMR (CDCl₃) δ 159.6, 139.0, 138.5, 135.2, 134.0, 133.9, 130.8, 130.7, 128.6, 128.5, 128.1, 128.0, 127.9, 127.7, 127.6, 114.0, 101.1, 78.9, 77.5, 74.3, 73.5, 73.2, 72.5, 72.3, 68.1, 55.5, 26.1, 18.3, -4.5, -4.6. HRMS (ESI, MNa⁺) *m/z* calc for C₅₄H₆₆NaO₉Si 909.4374, found 909.4373.

4.13 *Z*-Homoallylic alcohol **14** from Wittig reaction

To a solution of **21** (370 mg, 0.4 mmol) in THF (10 mL) at 0 °C was added dropwise a 1M solution of Bu₄NF in THF (0.8 mL, 0.8 mmol). The reaction mixture was warmed to rt, stirred at this temperature for 2 h, then diluted with water and extracted with EtOAc. The organic phase was washed with brine, dried (Na₂SO₄), and concentrated *in vacuo*. The residue was dissolved in EtOAc (2 mL) and treated with Ac₂O (0.2 mL) and DMAP (5 mg). After stirring for 10 min at rt. the organic solvent was concentrated *in vacuo*, and the crude product was purified by FCC to give a homogeneous product (330 mg, 98%): *R_f* = 0.25 (30% EtOAc/hexane). DDQ (190 mg, 0.80 mmol) was added to a mixture of this material (330 mg, 0.40 mmol), CH₂Cl₂ (4.5 mL) and saturated aqueous NaHCO₃ (0.5 mL). The reaction mixture was stirred at rt for 30 min, then concentrated *in vacuo*. FCC of the residue gave **14** (160 mg, 95% brsm). This material was identical by TLC, ¹H and ¹³C NMR to a sample of **14** prepared via the CM route.

4.14 C-glycoside oxazine (22)

To a solution of **6** (165 mg, 0.197 mmol) in dry CH₃CH₂CN (4 mL) at –25 °C was added anhydrous K₂CO₃ (55 mg, 0.80 mmol) and IBr (243 mg, 1.18 mmol). The reaction was stirred at this temperature for 2h, then diluted with aqueous Na₂S₂O₃ and extracted with EtOAc. The organic phase was washed with brine and dried (Na₂SO₄), filtered, and concentrated *in vacuo*. The crude material was purified by FCC to give an inseparable mixture of **22** and an unidentified impurity (139 mg). The purity of **22** was estimated at ca. 85 mol% by ¹HNMR, corresponding to a yield of 62% of **22** from **7**. Repeated FCC gave a pure sample of **22**: R_f = 0.18 (0.5% EtOH/CH₂Cl₂); [α]_D¹⁸ 47 (c 1.5, CH₂Cl₂); ¹HNMR (C₆D₆) δ 7.70 (dd, *J* = 1.3 Hz, 2H), 7.50 (m, 2H), 7.42 (m, 2H), 7.33–7.18 (m, 14H), 5.47 (m, 1H), 5.19 (s, 1H), 5.11 (m, 1H), 4.77 (m, 2H), 4.70 (apparent d, *J* = 11.5 Hz, 1H), 4.61 (ABq, *J* = 11.0 Hz, δ = .06 ppm, 2H), 4.54 (m, 3H), 4.40 (m, 2H), 4.27 (dd, *J* = 4.5, 7.0 Hz, 1H), 4.07 (m, 2H), 3.96 (dd, *J* = 3.0, 5.2 Hz, 1H), 3.87 (dd, *J* = 3.0, 5.3 Hz, 1H), 3.45 (dd, *J* = 6.9, 10.3 Hz, 1H), 3.28 (t, *J* = 10.2 Hz, 1H), 2.57 (m, 1H), 2.35 (m, 1H), 1.73 (s, 3H). ¹³CNMR (C₆D₆) δ 169.7, 152.5, 139.5, 139.0, 137.8, 129.7, 129.0, 128.9, 128.8, 128.5, 128.0, 127.1, 103.2, 76.6, 75.7, 75.1, 74.3, 74.2, 73.2, 72.6, 72.0, 68.6, 68.2, 66.6, 59.0, 38.0, 30.5, 20.8. HRMS (ESI, MK⁺) *m/z* calc for C₄₄H₄₅Cl₃IKNO₉ 1002.0842, found 1004.0811.

4.15 C-glycoside oxazine (23)

To a solution of **7** (85 mg, 0.1 mmol) in dry CH₃CH₂CN (2.0 ml) at –78 °C was added anhydrous K₂CO₃ (56 mg, 0.4 mmol) and IBr (150 mg, 0.7 mmol). Processing of the reaction as as described for the iodocyclization of *E*-trichloroacetimidate **6**, and FCC of the crude product gave **23** (68 mg, 70%): R_f = 0.43 (20% EtOAc/hexane); [α]_D¹⁸ 11 (c 0.8, CH₂Cl₂); ¹HNMR (C₆D₆) δ 7.40–7.18 (m, 20H), 5.51 (m, 1H), 5.33 (s, 1H), 5.10 (t, *J* = 6.2 Hz, 1H), 4.73 (m, 2H), 4.60 (ABq, *J* = 11.0 Hz, δ = 0.05 ppm, 2H), 4.52 (m, 3H), 4.35 (m, 2H), 4.08 (m, 1H), 4.02 (dd, *J* = 5.3, 10.3 Hz, 1H) 3.96 (m, 2H), 3.90 (m, 1H), 3.78 (dt, *J* = 5.5, 10.0 Hz, 1H), 3.42 (dd, *J* = 1.8, 8.8 Hz, 1H), 3.36 (t, *J* = 10.3 Hz, 1H), 2.76–2.61 (m, 2H), 1.73 (s, 3H), ¹³CNMR (C₆D₆) δ 169.8, 153.0, 139.7, 139.1, 139.0, 137.7, 130.0, 129.6, 129.0, 128.9, 127.9, 127.1, 126.9, 102.4, 77.7, 75.7, 74.7, 74.2, 74.0, 73.2, 72.7, 72.0, 69.9, 68.3, 67.9, 61.6, 37.6, 30.6, 20.8. HRMS (ESI, MNa⁺) *m/z* calc for C₄₄H₄₅Cl₃INNaO₉ 986.1102, found 988.1075.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported by the National Science Foundation (#1301330). A Research Centers in Minority Institutions Program grant from the National Institute of Health Disparities (MD007599) of the National Institutes of Health (NIH), which supports the infrastructure at Hunter College, and a Clinical Translational Science Center award (TR000457) from the NIH are also acknowledged. We thank Dr. Matthew Devany and Ms. Rong Wang for help with NMR and optical rotation measurements, respectively.

References

1. Stocker BL, Timmer MSM. *Carbohydr Res.* 2014; 389:3–11. [PubMed: 24074806]
2. Stocker BL, Timmer MSM. *Chembiochem.* 2013; 14:1164–1184. [PubMed: 23780905]
3. Rasmussen JM, Hermetter A. *Prog Lipid Res.* 2008; 47:436–460. [PubMed: 18582501]
4. Butters TD, Dwek RA, Platt FM. *Chem Rev.* 2000; 100:4683–4696. [PubMed: 11749362]
5. Rawat SS, Johnson BT, Puri A. *Biosci Rep.* 2005; 25:329–343. [PubMed: 16307380]
6. Lingwood CA, Mannis A, Mahfoud R, Khan F, Binnington B, Mylvaganam M. *Chem Phys Lipids.* 2010; 163:27–35. [PubMed: 19781539]
7. Takuya T, Mori K. *Trends Glycosci Glycotech.* 2010; 22:280–295.
8. Banchet-Cadeddu A, Hénon E, Dauchez M, Renault J-H, Monneaux F, Haudrechy A. *Org Biomol Chem.* 2011; 9:3080–3104. [PubMed: 21394364]
9. Postema, MHD. *C-Glycoside Synthesis.* CRC Press; Boca Raton FL: 1995.
10. Levy, D.; Tang, C. *The Synthesis of C-Glycosides.* Pergamon; Oxford: 1995.
11. Jiménez-Barbero J, Espinosa JF, Asensio JL, Cañada FJ, Poveda A. *Adv Carbohydr Chem Biochem.* 2001; 56:235–284.
12. Yuan X, Linhardt RJ. *Curr Top Med Chem.* 2005; 5:1393–1430. [PubMed: 16305537]
13. Lalitha K, Muthusamy K, Prasad YS, Vemula PK, Nagarajan S. *Carbohydr Res.* 2015; 402:158–171. [PubMed: 25498016]
14. Dondoni A, Marra A. *Chem Rev.* 2000; 100:4395–4421. [PubMed: 11749352]
15. Nolen EG, Watts MH, Fowler D. *Org Lett.* 2002; 4:3963–3965. [PubMed: 12599503]
16. Gustafsson T, Saxin M, Kihlberg J. *Org Chem.* 2003; 68:2506–2509.
17. Chen G, Schmieg J, Tsuji M, Franck RW. *Org Lett.* 2004; 6:4077–4080. [PubMed: 15496103]
18. Wipf P, Pierce JG. *Org Lett.* 2006; 8:3375–3378. [PubMed: 16836409]
19. Chen G, Chien M, Tsuji M, Franck RW. *Chembiochem.* 2006; 7:1017–1022. [PubMed: 16795118]
20. Pu J, Franck RW. *Tetrahedron.* 2008; 64:8618–8629. [PubMed: 19746154]
21. Liu Z, Byun H-S, Bittman R. *Org Lett.* 2010; 12:2974–2977. [PubMed: 20518525]
22. Liu Z, Bittman R. *Org Lett.* 2012; 14:620–623. [PubMed: 22233351]
23. Thota VN, Gervay-Hague J, Kulkarni SS. *Org Biomol Chem.* 2012; 10:8132–8139. [PubMed: 22961309]
24. Thota VN, Brahmaiah M, Kulkarni SS. *J Org Chem.* 2013; 78:12082–12089. [PubMed: 24199837]
25. Giannis A, Sandhoff K. *Tetrahedron Lett.* 1985; 26:1479–1482.
26. Roe BA, Boojamra CG, Griggs JL, Bertozzi CR. *J Org Chem.* 1996; 61:6442–6445. [PubMed: 11667491]
27. Evans DA, Trotter BW, Côté B. *Tetrahedron Lett.* 1998; 39:1709–1712.
28. Cui J, Horton D. *Carbohydr Res.* 1998; 309:319–330.
29. McGarvey GJ, LeClair CA, Schmidtmann BA. *Org Lett.* 2008; 10:4727–4730. [PubMed: 18826234]
30. Altiti AS, Mootoo DR. *Org Lett.* 2014; 16:1466–1469. [PubMed: 24559301]
31. For syntheses of C-KRN7000, see ref ^{17–22}.
32. Cardillo G, Orena M, Sandri S. *Pure Appl Chem.* 1988; 60:1679–1688.
33. Lee H-S, Kang SH. *Synlett.* 2004; 16:1673–1685.
34. Chamberlin AR, Mulholland RL Jr, Kahn SD, Hehre WJ. *J Am Chem Soc.* 1987; 109:672–677.
35. Cipolla L, La Ferla B, Lay L, Peri F, Nicotra F. *Tetrahedron: Asymmetry.* 2000; 11:295–303.
36. Leeuwenburgh MA, van der Marel GA, Overkleeft HS. *Cur Opin Chem Biol.* 2003; 7:757–765.
37. Paquette LA, Zeng Q, Tsui H-C, Johnston JN. *J Org Chem.* 1998; 63:8491–8509.
38. Reitz AB, Nortey SO, Jordan AD Jr, Mutter MS, Maryanoff BE. *J Org Chem.* 1986; 51:3302–3308.
39. Maryanoff BE, Reitz AB. *Chem Rev.* 1989; 89:863–927.

- α -C-glycosyl-linked homoallylic trichloroacetimidates were prepared
- Iodocyclization of these substrates gave highly substituted C-linked iodo-oxazines
- *E*- and *Z*-alkenes favored *anti* and *syn* 1,3-amino alcohol motifs, respectively
- These products are potential precursors to C-glycosides of the glycolipid KRN7000

Scheme 1.
C-glycosphingolipids via intramolecular nitrogen delivery

Scheme 2.

Homoallylic trichloroacetimidate precursors for C-glycosides of KRN7000

Scheme 3.

Cross metathesis strategy for homoallylic trichloroacetimidates

Scheme 4. Wittig strategy for *Z*-homoallylic trichloroacetimidate

Scheme 5. Iodocyclization of *E*- and *Z*-homoallylic trichloroacetimidates